Celldex Therapeutics Business Summary

Celldex Therapeutics, Inc. (CLDX) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic licensing agreements, research collaborations, and grants, though it currently operates as a pre-commercial entity with minimal trailing twelve-month revenue. The company maintains a single operating segment focused on the discovery, development, and commercialization of novel antibody-based therapeutics targeting mast cell-driven inflammatory, allergic, and autoimmune disorders. Its lead asset, barzolvolimab (CDX-0159), is a humanized monoclonal antibody currently in Phase 3 registrational trials for Chronic Spontaneous Urticaria (CSU) and other mast cell-mediated conditions. Within the competitive landscape, Celldex contends with mid-cap biotechnology firms such as Alkermes (ALKS), Amicus Therapeutics (FOLD), and Dynavax Technologies (DVAX). Celldex distinguishes itself through its specialized focus on KIT inhibition and mast cell biology, positioning it as a potential first-in-class leader in the specialized immunology market for chronic inducible urticarias. The company was co-founded by Anthony S. Marucci and Tibor Keler, Ph.D., both of whom possess extensive pedigrees from Medarex, Inc. (acquired by Bristol-Myers Squibb). Marucci serves as President and CEO, bringing over two decades of financial and operational leadership, while Keler serves as Executive Vice President and Chief Scientific Officer (CSO), overseeing the company’s proprietary antibody technology platforms. The leadership team was recently bolstered by the November 2025 appointment of Teri Lawver as Chief Commercial Officer, who previously managed a $4 billion global business at Dexcom and held senior roles at Johnson & Johnson. Other key executives include Chief Medical Officer Diane Young, M.D., formerly of Novartis Oncology, and CFO Sam Martin. Celldex is supported by a seasoned Board of Directors, including Chair Karen Shoos and former J&J executive Denice M. Torres, and maintains significant institutional backing from major investors such as The Vanguard Group, BlackRock, and BB Biotech.